Currently, intravitreal injection of anti-VEGF agents including aflibercept and ranibizumab is mainstream for treating patients with diabetes-related eye diseases; however, there are still numerous such patients who do not respond to the anti-VEGF treatment or develop resistance to the anti-VEGF therapy. This evidence concerns the gene VEGFA and diabetes mellitus.